Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, 24-Month, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Amyloid-Imaging Positron Emission Tomography (PET) and Safety Study of ACC-001 and QS-21 Adjuvant in Subjects With Mild to Moderate Alzheimer's Disease.

Trial Profile

A Phase 2, 24-Month, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Amyloid-Imaging Positron Emission Tomography (PET) and Safety Study of ACC-001 and QS-21 Adjuvant in Subjects With Mild to Moderate Alzheimer's Disease.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Jan 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vanutide cridificar (Primary) ; QS 21
  • Indications Alzheimer's disease
  • Focus Biomarker; Therapeutic Use
  • Acronyms ACCTION
  • Sponsors JANSSEN Alzheimer Immunotherapy

Most Recent Events

  • 27 Feb 2014 According to ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
  • 21 Aug 2013 Pfizer reported that the development of this vaccine has been discontinued. This, and one other PET imaging trial underway in the US will continue, as they are providing biomarker data.
  • 17 Jan 2012 Planned End Date changed from 1 Aug 2014 to 1 Feb 2014 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top